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Human immunodeficiency virus type 1 (HIV-1) subtype C is now responsible for more than half of all HIV-1 infections in the
global epidemic and for the high levels of HIV-1 prevalence in southern Africa. To facilitate studies of the biological nature
and the underlying molecular determinants of this virus, we constructed eight full-length proviral clones from two asymp-
tomatic and three AIDS patients infected with HIV-1 subtype C from Botswana. Analysis of viral lysates showed that Gag, Pol,
and Env structural proteins were present in the virions. In four clones, the analysis suggested inefficient envelope
glycoprotein processing. Nucleotide sequence analysis of the eight clones did not reveal frameshifts, deletions, premature
truncations, or translational stop codons in any structural, regulatory, or accessory genes. None of the subtype C clones were
replication competent in donor peripheral blood mononuclear cells (PBMCs), macrophages, Jurkattat cells, or U87.CD4.CCR5
cells. However, infection by two clones could be rescued by complementation with a functional subtype C envelope clone,
resulting in a productive infection of PBMCs, macrophages, and U87.CD4.CCR5 cells. © 2000 Academic PressINTRODUCTION
The human immunodeficiency virus type 1 (HIV-1) pan-
demic is characterized by extensive genetic variation as
a result of a high error rate of the viral reverse transcrip-
tase (RT) and RNA polymerase, high viral replication,
viral genome recombination, immune selection, and viral
phenotype switching (Drosopoulos et al., 1998; Preston
t al., 1988). HIV-1 sequences have been classified into
hree groups, designated M (major), O (outlier), and N
non-M, non-O) (Gurtler et al., 1994; Kostrikis et al., 1995;
Leitner et al., 1995; Loussert-Ajaka et al., 1995; Myers et
al., 1995; Simon et al., 1998; Vanden Haesevelde et al.,
1994). The majority of HIV-1 infections are caused by
viruses in the M group, which is subdivided into at least
10 genetic subtypes. The global distribution of the sub-
types is uneven, with subtypes A, C, and D predominat-
ing in sub-Saharan Africa, subtype B in Europe, North
America, and South America, and subtypes C and E in
Asia. Subtype C is the dominant subtype in regions with
the highest prevalence of HIV-1 infection, including
South Africa, Malawi, Zambia, Namibia, Zimbabwe, Ethi-
opia, and Botswana (Birx et al., 1996; Essex, 1999; Hu et
al., 1996; Ping et al., 1999). Subtype C is also the pre-
dominant subtype in India (Cassol et al., 1996; Dietrich et
al., 1993; Galai et al., 1997; Hu et al., 1996).
Most information on the molecular mechanisms un-
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390derlying HIV-1 pathogenesis has come from primary iso-
lates and subtype B clones. Recently, near full-length
genome non-B subtype viral sequences have been re-
ported (Gao et al., 1998; Lole et al., 1999; Novitsky et al.,
1999). Biological and phenotypic characterizations of
HIV-1 subtype C molecular clones have not been re-
ported. Amino acid sequence analysis shows that sub-
type differences reach 15, 10, and 24% in Gag, Pol, and
Env, respectively, raising the possibility of biological dif-
ferences between subtypes (Gao et al., 1998).
Viral molecular clones can be used to correlate genotype
to phenotype by the introduction of specific mutations or
other genomic alterations. Viral clones offer the advantage
of studying a virus as a unit rather than as different sub-
genomic fragments. In this report, we describe the gener-
ation of eight HIV-1 subtype C full-length molecular clones
from five different individuals. We analyzed the protein pro-
file of viral supernatants and their ability to infect primary
and continuous cell lines. A Botswana HIV-1 subtype C
gp160 clone was able to complement in trans and render
two clones infectious to peripheral blood mononuclear
cells (PBMCs), macrophages, and U87.CD4.CCR5 cells, al-
though individual noncomplemented virus stocks from
transfected cells were unable to establish a productive
infection of target cells.
RESULTS
PCR amplification and cloningUsing the approaches outlined in Fig. 1, we success-
fully amplified and cloned eight full-length clones from
391FULL-LENGTH HIV-1 SUBTYPE C FROM BOTSWANAfive HIV-1 seropositive patients. All clones were con-
FIG. 1. PCR amplification and cloning strategies. (A) Two subgenom
primer with a SacI restriction site while the antisense primer had an E
site and the antisense primer had an EcoRI site. The 59 fragment was c
The 39 fragment was then subcloned by digesting this plasmid with N
multiple cloning site of pBS-KS1 (SacI and EcoRI sites). A 9-kb HIV-1
vector was then digested and cloned into the NarI (in 59 LTR) and thefirmed to contain HIV-1 sequences by Southern blot anal-
ysis using probes corresponding to the LTR, gag, andenv genes. All clones represent primary isolates since
ments were amplified. The 59 fragment was amplified using a sense
te. The 39 fragment was amplified using a sense primer with an NcoI
into the SacI and EcoRI sites of pBluescript KS(1) (pBS-KS1) plasmid.
rtial digest) and EcoRI. (B) 59 LTR was amplified and cloned into the
ent previously amplified from genomic DNA and cloned into pCR 2.1
sites (in vector) to restore the full proviral genome.ic frag
coRI si
loned
coI (pa
C fragm
EcoRIthey were obtained directly from patients’ blood or prop-
agated for 14 days in PBMCs.
392 NDUNG’U ET AL.Generation of virus stocks
Molecular clones were transfected into 293T, COS-1,
and COS-7 cells to examine their ability to generate
infectious virus stocks. These three cell lines were used
because they are known to efficiently produce infectious
HIV-1 virions upon transfection but are not susceptible to
infection by free virions because they lack the receptors
needed for viral entry into cells. Production of viral par-
ticles was assessed by quantification of p24 antigen and
RT in tissue culture supernatants. For all three cell lines,
the clones released large amounts of p24 antigen and RT
by 60 h posttransfection. All three cell lines showed a
similar viral protein profile from their culture superna-
tants as assessed by Western blot (data not shown). As
expected there was correlation between the amounts of
p24 antigen and RT activity in each culture supernatant.
When these supernatants were used to infect donor
PBMCs, macrophages, U87.CD4.CCR5 cells, or Jurkattat
cells, none of the viral supernatants was able to estab-
lish a productive infection as determined by the failure to
observe an increase in p24 antigen in the cell superna-
tants over a 21-day period (not shown).
Western blot analysis
In an attempt to identify possible reasons for the lack of
infectivity of these molecular clones, we carried out West-
ern blot analysis of viral pellets from supernatants of trans-
fected cells. Four clones did not express the entire range of
virion-associated proteins known to be necessary for pro-
ductive infection. Four clones, designated C.96BW06.H51
(H51), C.96BW06.J4 (J4), C.96BW06.J7 (J7), and
C.96BW06.K18 (K18), appeared to express all virion-associ-
ated proteins as did the subtype B molecular clone
HXB2RU3CI (Fig. 2). We therefore decided to concentrate
further study on these four clones. Results from several
blots suggested that although these four clones expressed
all the expected virion-associated proteins, they showed
large amounts of unprocessed gp160 polyprotein relative to
processed gp120. It was previously shown that impairment
in the processing of the gp160 envelope precursor can
result in loss of viral infectivity (Dedera et al., 1992; Guo et
al., 1990; Syu et al., 1991). Our results thus led us to spec-
ulate that inefficient processing of the envelope protein
coupled with packaging of this nonfunctional form of the
protein into virions might explain the lack of infectivity of
these clones.
Envelope complementation of replication-defective
clones
To test whether these four clones were packaging an
unprocessed or defective envelope protein that resulted
in a lack of infectivity, we took advantage of a previously
described complementation assay that identifies func-
tional envelope proteins (Helseth et al., 1990). Using thissystem (with the modifications outlined under Materials
and Methods), we identified a functional HIV-1 subtype C
envelope clone from Botswana designated pSVIII/
MOLE1 (data not shown). All nine of the other envelope
clones repeatedly yielded chloramphenical acetyl trans-
ferase (CAT) levels lower than those obtained for the
positive control 89.6 envelope and were thus discarded.
When the pSVIII/MOLE1 clone was cotransfected with
each of the four full-length clones and the supernatants
used to infect PBMCs, macrophages, and U87.CD4.CCR5
cells, we found that in all cases, clones C.96BW06.J4 and
C.96BW06.J7 became infectious while clones
C.96BW06.H51 and C.96BW06.K18 remained noninfec-
tious (Fig. 3). In all three cell types, 500 pg total p24
antigen was used to infect cells. The amount of p24
antigen in the tissue culture supernatant of PBMCs in-
fected with C.96BW06.J4 (1MOLE1 env) increased
steadily and appeared to peak by day 15 (Fig. 3A). P24
amounts increased slowly for C.96BW06.J7 (1MOLE1
env) infection of PBMCs but they were still rising by day
21 postinfection. The titers of p24 antigen in all subtype
C clones were lower than for the subtype B clone,
HXB2RU3CI. In macrophages, all three clones appeared
to peak in p24 production by day 15, with virus produc-
tion for C.96BW06.J7 (1MOLE1 env) being about 50% of
what was observed for C.96BW06.J4 (1MOLE1 env) and
HXB2RU3CI (Fig. 3B). In U87.CD4.CCR5 cells, virus pro-
FIG. 2. Analysis of viral proteins by Western blot. COS-7, 293T, and
COS-1 cells were transfected with plasmid DNA containing the full-
length genomes of HIV-1 proviruses. Cell culture supernatants were
collected at 72 h posttransfection and overlaid on a 20% sucrose
cushion. After centrifugation, viral pellets were resuspended in lysis
buffer and viral proteins were separated by 4–15% linear SDS–PAGE.
Proteins were transferred to nitrocellulose membranes and analyzed
by immunoblot with human sera from an individual from Botswana
infected with HIV-1 subtype C.duction showed a sharp increase during the first week of
infection for all clones. Peak p24 production for the
o 500 p
was a
w
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393FULL-LENGTH HIV-1 SUBTYPE C FROM BOTSWANAsubtype C clones was about 65% of the HXB2RU3CI
subtype B positive control. In all three cell types, none of
the subtype C full-length clones replicated without the
pSVIII/MOLE1 envelope clone complementation. As ex-
pected, transfection of and infection by pSVIII/MOLE1
construct alone did not result in viral production.
Western blot analysis suggested inefficient gp160 pro-
cessing as a possible mechanism for the lack of infec-
tivity of the full-length clones. We therefore analyzed the
effect of the pSVIII/MOLE1 envelope construct cotrans-
fection on the Western blots of clones C.96BW06.H51,
C.96BW06.J4, and C.96BW06.J7 (Fig. 4). Amounts of
gp120 relative to gp160 were analyzed using NIH Image
software. We observed that pSVIII/MOLE1 complemen-
tation of C.96BW06.J4 and C.96BW06.J7 clones resulted
in a gp120 to gp160 ratio of approximately 2 (1.9),
whereas for C.96BW06.H51, the ratio was about 1. The
ratio in the noncomplemented noninfectious clones was
FIG. 3. Complementation of the full-length clones with a functional en
(C) U87.CD4.CCR5 cells. COS-1 cells were cotransfected with 2 and 1 m
antigen was quantified by ELISA. Culture supernatant corresponding t
target cells were washed three times with PBS and then new medium
FIG. 4. Western blot analysis of full-length viral lysates with and
ithout complementation with MOLE 1 envelope. Serum from an indi-
idual infected with HIV-1 subtype C was used to identify the proteins.approximately 1 in all cases. This result suggests a
deficient processing of gp160 and that a certain thresh-
old ratio of virion-packaged gp120 to gp160 may be
necessary for these subtype C clones to be infectious.
Sequence analysis
Nucleotide sequencing of the entire genome was car-
ried out for the four clones that expressed all virion-
associated proteins to confirm that all HIV-1 structural,
regulatory, and accessory genes were preserved. We did
not identify any obvious inactivating mutations such as
translational stop codons, frameshifts, premature trunca-
tions, or deletions in gag, pol, env, nef, rev, tat, vif, vpr, or
vpu. The LTR sequences were intact with motifs such as
the three NF-kB binding sites, the Sp1 binding site, and
the primer binding site preserved. The RNA packaging
signal sequence was present in all the clones. Phyloge-
netic analysis and variability plots confirmed the clones
to be of subtype C in every region of the genome (not
shown). An examination of the inferred V3 loop amino
acid sequences (Fig. 5) led us to predict that the new
sequences would most likely be of the NSI/R5 phenotype
as evidenced by a lack of basic amino acids at positions
11 and 25. We therefore decided to compare the new V3
sequences with those from a known CCR5-using sub-
type B clone, B.US.YU2. (Li et al., 1991; Choe et al., 1996,
58). There were seven amino acid differences in the V3
between the new sequences and the B.US.YU2 molecu-
lar clone. Most of the clones differed from the consensus
subtype C sequence by an isoleucine substitution for
valine at position 12. C.96BW06.K18 and C.96BWMOLE1
maintained the valine residue while C.96BW0407 had a
methionine substitution at this position. C.96BW06.J4,
C.96BW06.J7, and 96BW01B22 had a histidine to tyrosine
substitution at position 34. Clones C.96BW06.J4 and
(MOLE1) renders them infectious in (A) PBMCs, (B) macrophages, and
l-length and pSVIII/MOLE1 envelope clone, respectively. 72 h later, p24
g of p24 was then used to infect 3 3 106 cells. The following day, the
dded. Infection was monitored by p24 ELISA.velope
g of fulC.96BW06.J7 had single amino acid deletions of glu-
tamine 24 in the V3 loop.
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394 NDUNG’U ET AL.Since we observed in the Western blot that the pro-
cessing of gp160 to gp120 and gp41 was deficient, we
investigated whether the known proteolytic cleavage site
was conserved. The site sequence REKR was conserved
in all the envelopes except in C96BW06.H51 where the
second arginine is replaced by serine. Interestingly, it
has previously been shown that an arginine to threonine
substitution at that position affects gp160 envelope pro-
teolytic cleavage in subtype B viruses (Guo et al., 1990).
DISCUSSION
In this study, we have cloned, sequenced, and biologi-
ally characterized eight full-length HIV-1 subtype C viruses
rom Botswana. Our main findings were that two clones
C96BW06.J4 and C.96BW06.J7) generated infectious viral
tocks when complemented with an exogenous envelope
rotein from another subtype C sample from Botswana.
one of the virus stocks obtained after individual transfec-
ion of the eight molecular clones (C.BW01.B16, C.BW04.07,
.96BW06.H51, C96BW06.J4, C.96BW06.J7, C.96.BW06.K18,
.96BW15.C2, and C.96BW16.26) were infectious when
ested in PBMCs, macrophages, Jurkattat cells, and
87.CD4.CCR5 cells. We envision that these clones will
llow us to study in detail the effects of molecular changes
n the ability of subtype C viruses to infect cells, replicate,
nd cause cytopathic effects. To our knowledge, this is the
irst report in which subtype C infectious complements
ave been obtained directly from infected PBMCs. It has
reviously been shown that clones obtained after in vitro
assage may have altered biological characteristics that
ay render them somewhat less suitable in studies of
echanisms underlying pathogenesis (Sullivan et al., 1995).
ur infection system, while still limited by the need to carry
ut complementation, may overcome some of these prob-
ems.
FIG. 5. Envelope V3 alignment of the eight sequenced clones. The s
generated using the subtype C genomes from the HIV-1 database (KoWe suggest at least two potential mechanisms (or
heir combination) of the observed HIV-1 infection seen fpon transfection with the envelope clone. The first
ight be a simple complementation that leads to only
ne round of infection since the genome packaged into
irions is defective. The second mechanism might in-
olve a recombination event resulting in repair of the
efective genome, as has been previously observed (Sa-
aie et al., 1992). Further study is warranted to evaluate
he contribution of each component/mechanism to the
IV-1 subtype C infection seen. Attempts are also ongo-
ng to construct a full-length clone from the sample
96BW.MOLE1 in order to further characterize this virus.
n infectious subtype C molecular clone has previously
een reported from an Indian sample after in vitro culture
of virus in continous cell lines (Mochizuki et al., 1999).
The clones described in this article were obtained di-
rectly from PBMCs of infected persons or were cultured
only briefly in donor PBMCs and therefore represent
primary isolates. Importantly, samples from which these
subtype C clones were generated are from southern
Africa, where some of the highest HIV-1 seroprevalence
rates in the world are found.
There are previous reports that defective viral ge-
nomes are frequently encountered in the PBMCs of HIV-
1-infected individuals (Sanchez et al., 1997). In such
cases, it has been possible to define the molecular basis
for replication incompetence. It is puzzling that no obvi-
ous mutations could account for lack of infectivity in all
the sequenced clones in our study. Our results suggest
that beyond obvious inactivating mutations, the molecu-
lar determinants of viral infectivity may be more complex
than previously thought.
Subtype C viruses display certain unique genetic char-
acteristics that may lead to altered biological activity.
These viruses possess Tat and Rev proteins that are
prematurely truncated and they have a 15-bp insertion at
ces are compared to the consensus subtype V3. The consensus was
al., 1997).the 59 end of the vpu reading frame (Gao et al., 1998). So
ar, no unique biological characteristics have been
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395FULL-LENGTH HIV-1 SUBTYPE C FROM BOTSWANAmapped to these genetic features. Recently, it has been
shown that subtype C viruses almost exclusively use the
CCR5 chemokine receptor as a coreceptor for entry into
cells while other subtypes employ other coreceptors as
well (Bjorndal et al., 1999; Ping et al., 1999; Tscherning et
al., 1998). Since this coreceptor appears to be overrep-
resented in the female genital tract (Patterson et al.,
1998), it is plausible that subtype C viruses are more
efficient in infecting the cells that line the genital mu-
cosa. We and others have also shown that HIV-1C vi-
ruses possess three or four NF-kB enhancer copies in
he LTR compared to the conventional two copies in
ubtype B (Gao et al., 1996; Montano et al., 1997; Salmi-
nen et al., 1996). We have further demonstrated that the
extra NF-kB sites in HIV-1 subtype C are associated with
ncreased responsiveness to p65/Rel A and to the proin-
lammatory cytokine TNF-a (Montano et al., 1997, 2000).
thers have shown that HIV-1 subtypes may differ in the
romoter/enhancer activities of their LTRs, with HIV-1C
isplaying higher activity levels (Naghavi et al., 1999).
There is some evidence that infection with HIV-1 sub-
ype C may be associated with higher plasma RNA levels
nd significantly lower CD4 lymphocyte counts than sub-
ypes A or D (Neilson et al., 1999). It has also been
suggested that HIV-1 genotypes may be spreading at
different rates in Tanzania, with subtype C viruses being
at an advantage (Renjifo et al., 1998). In Senegal, subtype
appeared to be associated with faster disease pro-
ression than subtype A (Kanki et al., 1999). Recombinant
enomes of HIV-1 in Tanzania have also been found to
ontain an uneven representation of the envelope V3
oop from different subtypes, with subtype C V3 having a
igher representation than would be expected (Renjifo et
l., 1999). Although these studies are invaluable in track-
ng changes in the HIV-1 epidemic landscape, they are
nable to provide biological explanations for the ob-
erved trends. Studies with HIV-1 molecular clones such
s those described in this report may help provide some
nswers to these questions. Finally, the reagents de-
T
Demographic and Clinical Cha
Patient Age Sex
C
in
96BW01 29 M
96BW04 43 M
96BW06 25 M
96BW15 22 F
96BW16 28 F
96MOLE1 23 M
a The functional envelope clone was amplified from this sample.cribed in this report are expected to be useful as a
ource of antigens and in immunological response as-
v
Jays in the continuing effort to develop a clade C vaccine
or the southern Africa region.
MATERIALS AND METHODS
amples and DNA extraction
Samples for full-length HIV-1 amplification and cloning
ere obtained from anonymous donors in Gaborone and
olepolole, Botswana (Table 1). Patients’ serostatus was
stablished by enzyme-linked immunosorbent assay
ELISA) and Western blot analysis. Information regarding
ime and route of infection is not known. Patient clinical
lassification was carried out according to the Centers
or Disease Control and Prevention revised criteria (CDC,
987).
Genomic DNA was extracted directly from patients’
BMCs using the QIAamp Blood kit (Qiagen, Chatsworth,
A). For samples 96BW06 and 96MOLE1, patients’ PB-
Cs were cocultured in donor PBMCs for 2 weeks prior
o DNA extraction.
CR amplification and plasmid constructs
We used the Expand Long Template PCR System to
mplify the viral genome (Boehringer Mannheim, India-
apolis, IN). Two approaches were employed to clone
nd construct full-length HIV-1 proviral genomes (Fig. 1).
n the first strategy, which was used for sample 96BW06
four clones), the viral genome was amplified in two
ieces, a 5.7-kb (59 LTR to vif) fragment and a 4.3-kb (vif
o 39 LTR) fragment (Fig. 1A). The primers used for the
mplification of the 59 fragment (5.7 kb) were U3-SAC
59-CCGCGGGCGAGCTCGTGGAAGGGTTAATTTACT-
TAAGAAAAGGC-39) and BG15-NR (59-CGCGGATC-
CCATGGTGGAGGAAAGTGTCTGACAGCTTCCTG-39).
rimers for amplification of the 39 fragment (4.3 kb) were
G15-NF (59-CGCGGATCCGACACTTTCCTCCACCATG-
CTCCATAGCTTAG-39) and U5-R (59-CGCGGATCCGCG-
CGGCCGCGCACCCATCTCTCTCCTTCTAGCCT-39).
CR products were first cloned into the pCR 2.1-Topo
stics of Patients and Samples
rigin
ana CDC stage
No. of full-
length clones
ne II 1
ne II 1
ne I 4
ne IVC 1
ne IVC 1
lole III 1aABLE 1
racteri
ity of o
Botsw
Gaboro
Gaboro
Gaboro
Gaboro
Gaboro
Molepoector (InVitrogen, San Diego, CA) and propagated in
M109 competent cells (Promega Corp., Madison, WI).
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396 NDUNG’U ET AL.The 59 fragment was then digested with SacI and EcoRI
restriction enzymes and ligated into a pBluescript KS(1)
(pBS-KS1) vector (Stratagene, La Jolla, CA) that had
been linearized using the same enzymes. The 39 frag-
ent was then subcloned into this pBS-KS1 vector by
igestion with NcoI (partial digestion) and EcoRI en-
ymes.
The second strategy was to reconstruct four near-full-
ength sequences, previously submitted to GenBank (Ac-
ession Nos. AF110961, AF110963, AF11075, and
F110976), by insertion of the 59 LTR (Accession No.
F290031) (Fig. 1B). A 9-kb fragment was amplified using
heminested approach with the LA set of primers (Fujii
t al., 1997). In the first round amplification, 1 mg of DNA
as used as a template with primers LA1 and LA2. A
otal volume of 50 ml per PCR was used with a 300 mM
oncentration of each primer. We used 1.75 mM MgCl2
with 350 mM dNTPs per reaction. The PCR product was
run on 0.9% agarose gel and purified using the Qiaex II
gel extraction kit (Qiagen). Primers LA3 and LA2 were
used for the second-round reaction, with 5 ml of purified
PCR product from the first-round reaction. Cycling con-
ditions for both rounds of the PCR were as recom-
mended by the manufacturer. After initial cloning of the
PCR product in pCR 2.1 Topo vector, this fragment was
subcloned into a pB-KS1 vector into which a subtype C
TR had previously been cloned in the SacI and EcoRI
ites. Primers used for amplification of the 59 LTR were
3-SAC and PBS-ER (59-CGCGTCGACCCGGAATTC-
TCTCCTTCTAGCCTCCGCTAGTC-39). The sites used for
he subcloning were NarI, which was found to occur
aturally near the primer binding site in most LTR se-
uences, and EcoRI in the pBS-KS1 vector sequence.
ecombinant clones were screened by restriction anal-
sis, PCR, and Southern blot using LTR, gag, and env
rimers (data not shown). Clones with full-length ge-
omes were used for maxiprep DNA.
nvelope expressor plasmid
Genomic DNA was subjected to PCR amplification
sing the Expand Long Template PCR system with the
ollowing cycling conditions: a 2-min denaturation at
4°C followed by 10 cycles of 10 s at 94°C, 30 s at 57°C,
min at 68°C, and then another 20 cycles under these
onditions but with an additional 15 s per cycle for each
8°C extension step. The final extension was at 68°C for
min. The primers used were ETH-KPN (59-TATGGGG-
ACCTGTGTGG-39) and ETH-BAM (59-CTAAGGATCCGT-
CACTAATC-39). To create the MOLE 1 envelope expres-
or plasmid (pSVIII/MOLE1), the KpnI (6347)–BamHI
8475) fragment of the pSVIIIenv plasmid (Helseth et al.,
990) was replaced with the PCR amplicon from the
OLE1 sample. Nine other subype C envelope clones—
ach from a different individual—were likewise con-
f
Etructed for functional analysis. The envelope clones
ere then sequenced.
ells and cell lines
293T cells were propagated in RPMI 1640 medium
upplemented with 10% fetal bovine serum (FBS). COS-1
nd COS-7 cells were grown in Dulbecco’s modified
agle’s medium (DMEM) supplemented with 10% FBS.
87.CD4.CCR5 cells were maintained in DMEM supple-
ented with 15% FBS, 1 mg/ml puromycin, and 300 mg/ml
G418. Jurkattat cells were maintained in RPMI 1640 with
10% FBS and 800 mg/ml G418. PBMCs and macrophages
ere obtained from HIV-1 seronegative anonymous
ealthy donors and separated by density-gradient cen-
rifugation on lymphocyte separation medium (Organon
eknika, Corp., Durham, NC). PBMCs were cultured in
PMI 1640 supplemented with 10% FBS and were stim-
lated with 5 mg/ml phytohemagglutinin (Sigma, St.
Louis, MO) and 20 U/ml of interleukin-2 (Becton Dickin-
son Labware, Bedford, MA) for 48 to 72 h prior to infec-
tion.
Transfection and infection
Subconfluent COS-1, COS-7, and 293T cells were
transfected with 2–5 mg of plasmid DNA using the Fu-
ene 6 transfection reagent (Boehringer Mannheim).
XB2RU3CI, a macrophage-tropic subtype B molecular
lone (Trujillo et al., 1996; Wang et al., 1998), was used as
he positive control. Sixty to 72 h posttransfection, culture
upernatants were filtered through 0.2-mm-pore-size fil-
ter units (Nalgene, Rochester, NY) and HIV-1 virions were
quantified by p24 antigen ELISA (NEN Life Science Prod-
ucts, Boston, MA) and by the Quan-T-RT [3H] reverse
transcriptase assay (Amersham Pharmacia Biotech, Pis-
cataway, NJ). Equivalent amounts of virus (as determined
by amount of p24 antigen in culture supernatant) were
used to infect 3 3 106 PBMCs, macrophages,
87.CD4.CCR5 glioma cells, and Jurkattat cells. Twenty-
four hours postinfection, cells were washed three times
with phosphate-buffered saline and fresh medium was
then added. Infection of the target cells was monitored
for up to 21 days by p24 ELISA.
Envelope function analysis
To examine the ability of the subtype C envelope
clones to complement cell-free viral transmission, we
followed the method previously described by Helseth et
al. (1990) with some modifications. Briefly, COS-1 cells
were cotransfected with 1 mg pHXBDenvCAT and 2 mg of
the envelope expressor plasmid. The dual-tropic 89.6
envelope expressor plasmid (Sullivan et al., 1995) was
sed as a positive control. At 72 h posttransfection, the
ell supernatants were filtered through 0.2-mm-pore-sizeilter units (Nalgene) and p24 antigen was quantified by
LISA (NEN Life Science Products). We then used su-
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397FULL-LENGTH HIV-1 SUBTYPE C FROM BOTSWANApernatant containing 500 pg of p24 antigen to infect 5 3
105 U87.CD4.CCR5 cells in 2 ml of medium. The cells
were washed three times the following day with PBS.
Sixty to 72 h later, all supernatant was removed, and the
cells were washed three times with PBS. The cells were
then lysed and the amount of CAT in the lysate was
determined using the CAT ELISA kit (Boehringer Mann-
heim). A total of 10 different subtype C envelope clones
were examined using this protocol.
Viral pellets
To prepare viral proteins for Western blot analysis,
filtered culture supernatants from transfected cells were
centrifuged at 3000 rpm for 15 min. Supernatants were
then overlaid on 4 ml of 20% sucrose cushion and cen-
trifuged at 20,000 rpm (Beckman SW28 rotor) for 2 h. The
supernatant was then discarded and any remaining fluid
was dried using cotton swabs. The viral pellet was then
resuspended in 100–150 ml of lysis buffer (0.15 M NaCl,
.05 M Tris–HCl, pH 7.2, 1% Triton X-100, 1% sodium
eoxycholate, and 0.1% sodium dodecyl sulfate). The
otal amount of protein recovered was quantified by the
io-Rad Protein Assay kit (Bio-Rad, Hercules, CA).
welve micrograms of total protein for each sample was
hen mixed with reducing buffer (0.08 M Tris–HCl, pH 6.8,
.1 M dithiothreitol, 2% sodium dodecyl sulfate, 10% glyc-
rol, and 0.2% bromophenol blue), boiled for 3 min, and
esolved by 4–15% linear sodium dodecyl sulfate–poly-
crylamide gel electrophoresis (SDS–PAGE).
mmunoblotting
Resolved proteins were transferred passively by plac-
ng the gel between two nitrocellulose membranes
Schleicher and Schuell, Keene, NH) and placing a
eight on top of the cassette for 48 h. Viral proteins were
isualized by immunoblotting with a range of sera from
IV-1 seropositive individuals infected with subtype C
rom Botswana and individuals infected with subtype B
rom North America. Analysis of amounts of gp120 pro-
ein relative to gp160 in the viral lysate was performed on
Macintosh computer using the public domain NIH
mage program (developed at the U.S. National Institutes
f Health and available on the Internet at http://rsb.info.
ih.gov/nih-image/).
equencing and sequence analysis
A primer walking strategy on purified plasmid DNA
as used for sequencing both strands of the genome,
ith overlapping contiguous sequences obtained
hroughout the genome to ensure accuracy of sequence
utput (primers were approximately 300 bp apart on
ach strand of the genome). Over 100 different sequenc-
ng primers were used, and their sequences are avail-
ble on request. Automatic sequencing was carried out
sing a Model 373A automated DNA Sequenator (Ap-lied Biosystems, Inc., Foster City, CA). Individual contig-
ous sequences of proviral DNA were assembled using
he Sequencher program (Gene Codes Corp., Ann Arbor,
I). Multiple sequence alignment was carried out using
he clustal W program and the Lasergene program. The
jplot (Perriere and Gouy, 1996) and Treeview (Page,
996) programs were used to view sequence related-
ess. The program SWAN (Proutski and Holmes, 1998),
sing a 300-bp sliding window with a step-wise incre-
ent of 30 bp, assessed variability patterns. All gaps
ere excluded during sequence analysis. The Recombi-
ant Identification Program (Siepel et al., 1995) and HIV
ubtyping Basic BLAST (Altschul et al., 1997) were used
o assess viral recombination (data not shown).
enBank accession numbers
New sequences described in this study are available
nder GenBank Accession Nos. AF290027–AF290032.
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